CoChat
Sign Up
Cited by 255Multiple Myeloma Research and TreatmentsVenous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study

Open access
Kristinsson, Sigurdur Y., Pfeiffer, Ruth M., Björkholm, Magnus, Goldin, Lynn R., Schulman, Sam, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Wahlin, Anders, Turesson, Ingemar, Landgren, Ola·2010·Blood
DOI 10.1182/blood-2009-11-252072PMC PMC2890150
Open this paper in CoChat — free account

Abstract

Patients with multiple myeloma (MM) have an increased risk of venous thrombosis. Interestingly, excess risk of venous thromboembolism has been observed among patients with monoclonal gammopathy of undetermined significance (MGUS). Using population-based data from Sweden, we assessed the risks of venous and arterial thrombosis in 18,627 MM and 5326 MGUS patients diagnosed from 1958 to 2006, compared with 70,991 and 20,161 matched controls, respectively. At 1, 5, and 10 years after MM diagnosis, there was an increased risk of venous thrombosis: hazard ratios (95% confidence intervals) were 7.5 (6.4-8.9), 4.6 (4.1-5.1), and 4.1 (3.8-4.5), respectively. The corresponding results for arterial thrombosis were 1.9 (1.8-2.1), 1.5 (1.4-1.6), and 1.5 (1.4-1.5). At 1, 5, and 10 years after MGUS diagnosis, hazard ratios were 3.4 (2.5-4.6), 2.1 (1.7-2.5), and 2.1 (1.8-2.4) for venous thrombosis. The corresponding risks for arterial thrombosis were 1.7 (1.5-1.9), 1.3 (1.2-1.4), and 1.3 (1.3-1.4). IgG/IgA (but not IgM) MGUS patients had increased risks for venous and arterial thrombosis. Risks for thrombosis did not vary by M-protein concentration (> 10.0 g/L or < 10.0 g/L) at diagnosis. MGUS patients with (vs without) thrombosis had no excess risk of MM or Waldenström macroglobulinemia. Our findings are of relevance for future studies and for improvement of thrombosis prophylaxis strategies.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2009-11-252072

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Research works printed but not linked: 3

  1. Rajkumar, 2006, Lenalidomide and venous thrombosis in multiple myeloma., N Engl J Med, 354, 2079, 10.1056/NEJMc053530 · DOI
  2. Socialstyrelsen, 2007, Cancer Incidence in Sweden 2006
  3. Anonymous, 1998, Patientregistret 1987-1996: Kvalitet och innehåll (Swedish)

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Kristinsson, S. Y., Pfeiffer, R. M., Björkholm, M., Goldin, L. R., Schulman, S., Blimark, C., Mellqvist, U.-H., Wahlin, A., Turesson, I., & Landgren, O.
Affiliations
  • Karolinska University Hospital (SE)
  • National Institutes of Health (US)
  • Sahlgrenska University Hospital (SE)
  • Cancer Centre, Section of Hematology, Umea University Hospital, Umea, Sweden;
  • Department of Medicine, Section of Hematology, Malmö University Hospital, Malmö, Sweden; and
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2010-06-17
Volume
115
Issue
24
Pages
4991-4998
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2009-11-252072
PMC
PMC2890150
OpenAlex
W1975136159
Cited by
255
References
44
Citations by year
2026: 12 · 2025: 17 · 2024: 21 · 2023: 25 · 2022: 19 · 2021: 17 · 2020: 20 · 2019: 14 · 2018: 11 · 2017: 10 · 2016: 19 · 2015: 10 · 2014: 15 · 2013: 9 · 2012: 13
FWCI
9.03
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
National Institutes of Health
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
monoclonal gammopathy of undetermined significance, multiple myeloma, venous thrombosis, arterial thrombosis, venous thromboembolism, Waldenström macroglobulinemia, thrombosis risk, thromboprophylaxis
MeSH terms
Adult, Aged, Aged, 80 and over, Arteries, Female, Humans, Immunoglobulin A, Immunoglobulin G, Waldenstrom Macroglobulinemia, Male, Middle Aged, Multiple Myeloma, Paraproteinemias, Predictive Value of Tests, Registries, Risk Factors, Sweden, Veins, Proportional Hazards Models, Survival Analysis, Databases, Factual, Venous Thrombosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review